

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 August 2010 (12.08.2010)

(10) International Publication Number
WO 2010/090723 A2

PCT

(51) International Patent Classification:

A61K 31/519 (2006.01) *A61P 1/16* (2006.01)
A61K 31/4196 (2006.01) *A61P 1/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2010/000283

(22) International Filing Date:

2 February 2010 (02.02.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/206,774 4 February 2009 (04.02.2009) US
61/277,284 22 September 2009 (22.09.2009) US

(71) Applicants (for all designated States except US): **UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.** [US/US]; Boyd Graduate Research Center, D.w. Brooks Drive, Athens, GA 30602-7411 (US). **UNIVERSITY OF NEWCASTLE UPON TYNE** [GB/GB]; King's Gate, Newcastle Upon Tyne NE1 7RU (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MANN, Jelena** [GB/GB]; 56 Newlands Avenue, Gosforth, Newcastle Upon Tyne NE3 5PX (GB). **CHU, Chung, K.** [US/US]; 662 Garden Circle, Statham, GA 30666 (US). **MANN, Derek, A.** [GB/GB]; 56 Newlands Avenue, Gosforth, Newcastle Upon Tyne NE3 5PX (GB).

(74) Agent: **COLEMAN, Henry, D.**; Coleman Sudol Sapone, P.C., 714 Colorado Avenue, Bridgeport, CT 06605-1601 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: METHODS OF INHIBITING FIBROGENESIS AND TREATING FIBROTIC DISEASE

(57) Abstract: The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and/or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention.



WO 2010/090723 A2

Methods of Inhibiting Fibrogenesis and Treating Fibrotic Disease

Field of the Invention

The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response of the injured liver. Methods of inhibiting fibrogenesis in a patient, including liver fibrogenesis and treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol) as well as fibrotic disease states and conditions including fibrotic liver diseases and conditions, are further aspects of the present invention.

Related Applications and Grant Support

This application claims the benefit of priority of United States provisional application serial nos. US61/206,774, filed February 4, 2009, entitled "Methods of Inhibiting Liver Fibrogenesis and Treating Liver Damage, Including Cirrhosis of the Liver" and 61/277,284, filed September 22, 2009, entitled "Methods of Inhibiting Fibrogenesis and Treating Fibrotic Disease", both of which applications are incorporated by reference in their entirety herein.


This application was supported by NIAAA/NIH grants, R21AA016682, R24AA012885, and P50AA11999. Consequently, the government retains certain rights in the invention.

Background and Brief Description of the Invention


The liver neutralises microbial infections and detoxifies xenobiotics. However, exposure to these agents results in liver cell damage which necessitates a rapid and efficient wound-healing response. Central to this wound-healing is the local production of scar-forming myofibroblasts. A rapid response mechanism for generating hepatic myofibroblasts is the transdifferentiation of resident quiescent retinoid-storing hepatic stellate cells (Friedman SL 2008). Myofibroblast transdifferentiation (MTD) also occurs with pancreatic stellate cells and renal mesangial cells in the injured pancreas and kidney respectively (Omery *et al* JCI 2007, Simonson MS 2007), suggesting biological conservation of the process. MTD is associated with global changes in gene transcription required for the cell to adopt the pro-inflammatory and pro-fibrogenic characteristics of the myofibroblast (Smart

and Mann 2002). Regulation of MTD-associated gene expression is poorly understood but must be under strict control to prevent inappropriate wound healing (or fibrosis). Here we describe a novel epigenetic relay that is initiated by loss of expression of microRNA miR132 and which culminates in transcriptional silencing of PPAR γ , a master negative regulator of MTD of hepatic stellate cells (She H *et al* 2005, Tsukamoto H *et al* 2006). We further describe two key components of the relay pathway, MeCP2 and EZH2, as critical regulators of hepatic wound-healing.

The present invention relates to the use of a compound according to the chemical structure **Ia**:



Where B is



W is C-H, O or S (preferably C-H or O, more preferably C-H) such that the bond between W and the adjacent carbon atom is a double bond when W is C-H and a single bond when W is O or S;

V is C-A'', O or S, preferably with the proviso that when V is O or S, W is O or S (preferably, both V and W are O);

A is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A' is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A'' is H or OR¹, with the proviso that when A' is OR², A is H; and when A is OR², A' is H;

X is C-R³ or N;

Y is C-R³ or N; preferably X or Y is N and X and Y are not both simultaneously N;

R_z is H or a C₁-C₃ alkyl group, optionally substituted with OH (preferably H);

R³ is H, a halogen or C₁-C₃ alkyl;

D is H, a halogen (preferably F, Cl or Br) or NR^{1a}R²;

E is absent (when G is NHR²) or H (when G is O);

G is O or NR^{1a}R²;

J is N or C-R⁴;

K is N or C-H;

R⁴ is H, halogen (F, Cl, Br, I), CN, -C(=O)NH₂, NH₂, NO₂, -C=C-H (cis or trans) or -C≡C-H;

R_a is H or CH₃;


Each R¹ is independently H, an acyl group, a C₁—C₂₀ alkyl or ether group, an amino acid (D or L), a phosphate, diphosphate, triphosphate, phosphodiester group;

Each R^{1a} and R² is independently H, an acyl group, a C₁—C₂₀ alkyl or ether group, an amino acid (D or L) or together R^{1a} and R² form a C₃-C₇ cycloalkyl group; and

pharmaceutically acceptable salts, solvates or polymorphs thereof to treat and/or inhibit fibrogenesis in a patient or subject especially including fibrotic disease and/or conditions, including liver fibrosis and/or cirrhosis of the liver, in particular fibrosis and cirrhosis which may be caused by viruses, chemical and/or drugs.

Certain alternative embodiments for use in treating and/or inhibiting fibrogenesis, including fibrotic disease and/or conditions as otherwise described herein include compounds wherein W and V are both O and wherein B, A, A' and R¹ are the same as described for formula **Ia** above.

Alternative preferred compounds for use in treating and/or inhibiting fibrogenesis, including fibrotic disease and/or conditions as otherwise described herein include compounds according to the chemical structure **Ib** (W is a C-H):


**Ib**

Wherein B, A, A', A'' and R¹ are the same as described for formula **Ia** above.

Fibrotic diseases which may be treated according to the present invention include, for example, liver fibrosis (alcoholic, viral, autoimmune, metabolic and hereditary chronic disease), renal fibrosis (e.g., resulting from chronic inflammation, infections or type II diabetes), lung fibrosis (idiopathic or resulting from environmental insults including toxic particles, sarcoidosis, asbestosis, hypersensitivity pneumonitis, bacterial infections including tuberculosis, medicines, etc.), interstitial fibrosis, systemic scleroderma (autoimmune disease in which many organs become fibrotic), macular degeneration (fibrotic disease of the eye), pancreatic fibrosis (resulting from, for example, alcohol abuse and chronic inflammatory disease of the pancreas), fibrosis of the spleen (from sickle cell anemia, other blood disorders) cardiac fibrosis (resulting from infection, inflammation and hypertrophy), mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, fibrotic complications of surgery, especially surgical implants, injection fibrosis and secondary conditions and disease states of fibrosis. Secondary conditions and disease states of fibrosis include for example, cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome and rheumatoid arthritis, among others.


In certain preferred aspects of the present invention (especially including compounds according to formula **Ib**), A is OH, A' is H and A'' is OH, J is N or CR⁴, K is N or CH, X is N, Y is CR³, E is absent and G is NHR². In other preferred embodiments, J is N, K is CH and G is O or NHR². In many preferred embodiments, R¹ and R² are both H. In certain preferred embodiments, R⁴ is an acetylenic group.

In other embodiments, the preferred compound is




Where R^1 , R^2 , R^4 , X and Y are the same as described above. Other preferred compounds may be readily gleaned from the description of the invention which follows.

In still other preferred embodiments, the compound is according to the chemical structure **Ic** hereinbelow:




Where B' is



Or pharmaceutically acceptable salts, solvates or polymorphs thereof.

In still other preferred embodiments compounds which may be used in the present invention include the following:



Where D is H, F, Cl or Br, preferably F or Cl, more preferably Cl,
Or pharmaceutically acceptable salts, solvates or polymorphs thereof.

In alternative embodiments, the compound as described hereinabove, may be conjugated to an antibody (monoclonal or polyclonal) which binds to MeCP2 or EZH2 (anti-MECP2 or anti-EZH2). Alternatively, the above antibodies may be used in the absence of conjugation to inhibit MeCP2 or EZH2 in order to inhibit fibrogenesis in a patient or subject, including liver fibrogenesis and to treat cirrhosis of the liver, as well as fibrotic disease and disease states and conditions which occur secondary to fibrogenesis and/or fibrotic disease.

The present invention also relates to pharmaceutical compositions comprising an effective amount of any one or more of the compounds described above (especially compounds conjugated to mono and/or polyclonal antibodies), optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

Thus, the present application is directed to the inhibition of fibrogenesis, including liver fibrogenesis in a patient in need thereof, and/or the treatment of cirrhosis of the liver (which may be caused for example, by a virus, a chemical or drug) comprising administering an effective amount of one or more compounds or anti-MeCP2 and/or anti-EZH2 antibodies (including compounds conjugated to anti-MECP2 and/or anti-EZH2 antibodies) according to the present invention optionally in combination with a pharmaceutically acceptable carrier,

additive or excipient to said patient. Pharmaceutical compositions based upon these antibodies and/or nucleoside compounds in effective amounts in combination with a pharmaceutically acceptable carrier, additive or excipient are additional aspects of the present invention.

The present invention also relates to the inhibition of methylation of DNA and RNA in cells comprising exposing cells, especially including liver cells to an effective of a compound as otherwise disclosed herein. A method of inhibiting the methylation of DNA and/or RNA in cells, especially liver cells, in a patient comprises administering an effective amount of a compound as otherwise described herein to said patient.

The present invention also relates to method for inhibiting and/or treating fibrotic diseases including, for example, liver fibrosis (alcoholic, viral, autoimmune, metabolic and hereditary chronic disease), renal fibrosis (e.g., resulting from chronic inflammation, infections or type II diabetes), lung fibrosis (idiopathic or resulting from environmental insults including toxic particles, sarcoidosis, asbestosis, hypersensitivity pneumonitis, bacterial infections including tuberculosis, medicines, etc.), interstitial fibrosis, systemic scleroderma (autoimmune disease in which many organs become fibrotic), macular degeneration (fibrotic disease of the eye), pancreatic fibrosis (resulting from, for example, alcohol abuse and chronic inflammatory disease of the pancreas), fibrosis of the spleen (from sickle cell anemia, other blood disorders) cardiac fibrosis (resulting from infection, inflammation and hypertrophy), mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, fibrotic complications of surgery, especially surgical implants, injection fibrosis and secondary conditions and disease states of fibrosis. Secondary conditions and disease states which occur as a consequence of or associated with fibrosis include for example, cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome and rheumatoid arthritis, among others. The method according to the present invention comprises administering an effective amount of one or more compounds according to the present invention to a patient at risk for a fibrotic disease or in need of therapy for a fibrotic disease or secondary disease state or condition thereof, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

Brief Description of the Figures

Figure 1- A.) PPAR γ expression in rat HSCs and MFB- Total RNA isolated from day 0 freshly isolated rat HSCs and day 10 cultures of same cells which had undergone MTF to become MFB. First strand cDNA was synthesised which was then utilised as a template in qPCR using primers for specific amplification of rat PPAR γ . The relative level of transcriptional difference was calculated and expressed as an average $\pm$ SEM from three independent cell preparations. Results are expressed as percent of PPAR γ expression in HSCs. B.) 100 μ g of crosslinked chromatin obtained from rat HSC or MFB was incubated with 10 μ g of anti RNAPolIII phospho Ser2. The protein/DNA complexes were immunoprecipitated using blocked StaphA membranes. DNA component of the immunoprecipitated complexes was separated from protein fraction using phenol/chloroform extraction followed by ethanol immunoprecipitation. Obtained DNA was used as template in qPCR reactions containing rat PPAR γ exon A1 specific primers. C.) 100 μ g of crosslinked chromatin obtained from rat HSC or MFB was incubated with 10 μ g of anti MeCP2 antibody. The protein/DNA complexes were immunoprecipitated using blocked StaphA membranes. Following the reversal of crosslinks, DNA component of the immunoprecipitated complexes was separated from protein fraction using phenol/chloroform extraction followed by ethanol immunoprecipitation. Obtained DNA was used as template in qPCR reactions containing rat PPAR γ exons A1, A2 and 1-6 specific primers. Negative control and baseline were set as 1 and remaining values shown in relation to this as fold enrichment relative to total input. D.) 5 $\times 10^6$ rat MFBs were electroporated as outlined in “Materials and methods”. 2 μ gs total siRNA designed to target rat MeCP2 was used per transfection. Control siRNA used was a validated, non-targeting siRNA. Total RNA was prepared from control or rat MeCP2 siRNA transfected cells 48h after the electroporation. First strand cDNA was synthesised which was then utilised as a template in qPCR using primers for specific amplification of rat PPAR γ . E.) Quiescent HSCs were isolated from wild type C57Bl6 or *mecp2*^{-/-} mice and allowed to transdifferentiate *in vitro* for 14 days. Total RNA was prepared from both C57Bl6 and *mecp2*^{-/-} MFB cell populations and first strand cDNA synthesised which was then utilised as a template in qPCR using primers for specific amplification of mouse PPAR γ . The relative level of transcriptional difference was calculated and expressed as an average $\pm$ SEM from three independent cell preparations. Results are expressed as percent of PPAR γ expression in wild type C57Bl6 MFBs.

Figure 2- **A.)** A small piece of frozen CCl₄ injured wild type or *mecp2*^{-/-} liver was mashed up and resuspended in PBS. Protein concentration of cell suspension was determined and 200µg whole cell extract denatured in SDS loading buffer and proteins separated by SDS PAGE. Protein was transferred onto membrane and immunoblotted for MeCP2. Representative of two separate experiments is shown. **B.)** RNA was isolated from a small piece of frozen CCl₄ injured wild type or *mecp2*^{-/-} liver. First strand cDNA was synthesised which was then utilised as a template in qPCR using primers for specific amplification of mouse PPAR γ . Results are expressed as percent of PPAR γ expression in wild type CCl₄ injured liver. **C.)** Quiescent HSCs were isolated from wild type C57Bl6 or *mecp2*^{-/-} mice and allowed to transdifferentiate *in vitro* for 14 days. Total RNA was prepared from both C57Bl6 and *mecp2*^{-/-} MFB cell populations and first strand cDNA synthesised which was then utilised as a template in qPCR using primers for specific amplification of mouse collagen 1. The relative level of transcriptional difference was calculated and expressed as an average $\pm$ SEM from three independent cell preparations. Results are expressed as percent of collagen 1 expression in wild type C57Bl6 MFBs. **D.)** Sirius Red immunostaining on sections cut from a chronically (3 weeks) CCl₄ injured wild type C57Bl6 or *mecp2*^{-/-} livers. Photomicrographs taken at x5 magnification show greater collagen deposition in wild type as compared to *mecp2*^{-/-} hemizygote animals indicative of a more severe fibrosis grade.

Figure 3- **A.)** Freshly isolated HSCs (day 0) or HSCs/MFBs harvested at day 1, 2, 3 and 7 following the isolation were resuspended in PBS, protein concentration determined and 30µg whole cell extract from each sample separated on SDS PAGE. Transferred protein was used to immunoblot for MeCP2 and β actin. **B.)** 20ng of cDNA from quiescent HSC or MFBs was used as a template for RT-PCR with primer pair specific for MeCP2 and β actin. The PCR was carried out over 30 or 23 cycles for MeCP2 and β actin respectively. **C.)** 20ng of cDNA from quiescent HSC or MFBs was used as a template for RT-PCR with primer pairs specific for sections of 3' UTR in MeCP2 mRNA. The transcripts were amplified over 30 cycles. The PCR product generated by primer pair 3'UTR1 started at 989bp 3' of MeCP2 stop codon; 3'UTR2 PCR product started at 1978bp 3' of the stop codon; 3'UTR3 at 4063bp at 3' of the stop codon; 3'UTR4 at 5162bp at 3' of the stop codon; 3'UTR5 at 6868bp at 3' of the stop codon and 3'UTR6 at 8401bp at 3' of the stop codon. **D.)** Micro RNAs were isolated from quiescent HSCs and MFBs using miRNeasy mini kit. Obtained total RNA was reverse transcribed using miScript Reverse Transcription Kit and rat miR132 in the samples detected

with miScript primer assay 218300. Results are expressed as percent of miR132 expression in HSCs. E.) to G.) 5×10^6 MFBs were mixed with $2 \mu\text{g}$ miR132 mimic or control siRNA and electroporated as outlined in “Materials and methods”. Cells were harvested 48 hours later for RNA and whole cell extract preparation. Micro RNA was isolated and detected as described in D.) see figure 3E.) for results that are expressed as percent of miR132 expression in control siRNA transfected MFBs. F.) Whole cell extracts obtained from miR132 or control siRNA transfected MFBs were separated by SDS-PAGE and transferred protein blotted for MeCP2 and β actin. G.) cDNA obtained in E.) was further used as template in qPCR using primer pair specific for PPAR γ . H.) Native chromatin was prepared from *in vitro* transdifferentiated C57Bl6 or *mecp2^{-y}* MFBs. $100 \mu\text{g}$ of native chromatin from either wild type or *mecp2^{-y}* MFBs was incubated with $10 \mu\text{g}$ of anti dimethyl H3K27, dimethyl H3K9 or dimethyl H3K4 and protein/DNA complexes were immunoprecipitated using blocked StaphA membranes. DNA component of the immunoprecipitated complexes was separated from protein fraction using phenol/chloroform extraction followed by ethanol immunoprecipitation. Obtained DNA was used as template in PCR reactions containing mouse PPAR γ promoter specific primers. All results are expressed as values above background calculated as fold enrichment relative to total input.

Figure 4- A.) $100 \mu\text{g}$ of crosslinked chromatin obtained from rat MFB was incubated with $10 \mu\text{g}$ of anti HP1 α . The protein/DNA complexes were immunoprecipitated using blocked StaphA membranes. Following the reversal of crosslinks, DNA component of the immunoprecipitated complexes was separated from protein fraction using phenol/chloroform extraction followed by ethanol immunoprecipitation. Obtained DNA was used as template in qPCR reactions containing rat PPAR γ exons A1, A2 and 1-6 specific primers. All results are expressed as values above background calculated as fold enrichment relative to total input. B.) $100 \mu\text{g}$ of native chromatin prepared from rat HSCs or MFBs was incubated with $10 \mu\text{g}$ of anti dimethyl H3K27 antibody. The protein/DNA complexes were immunoprecipitated using blocked StaphA membranes. DNA component of the immunoprecipitated complexes was separated from protein fraction using phenol/chloroform extraction followed by ethanol immunoprecipitation. Obtained DNA was used as template in PCR reactions containing rat PPAR γ promoter and exons A1, A2 and 1-6 specific primers. All results are expressed as values above background calculated as fold enrichment relative to total input. C.) Freshly isolated HSCs (day 0) or HSCs/MFBs harvested at day 1, 2, 3 and 7 following the isolation

were resuspended in PBS, protein concentration determined and 30µg whole cell extract from each sample separated on SDS PAGE. Transferred protein was used to immunoblot for EZH2 and β actin. **D.)** 5×10^6 rat MFBs were electroporated as outlined in “Materials and methods”. 2µgs total control siRNA or siRNA designed to target rat MeCP2 was used per transfection. Total RNA was prepared from control or rat MeCP2 siRNA transfected cells 48h after the electroporation. First strand cDNA was synthesised which was then utilised as a template in qPCR using primers for specific amplification of EZH2. **D.)** Quiescent HSCs were isolated from wild type C57Bl6 or *mecp2^{-/-}* livers and allowed to transdifferentiate *in vitro* for 14 days. Total RNA was prepared from C57Bl6 and *mecp2^{-/-}* MFB cell populations and first strand cDNA synthesised which was then utilised as a template in qPCR analysis of EZH2 expression. The relative level of transcriptional difference was calculated and expressed as an average ± SEM from three independent cell preparations. Results are expressed as percent of EZH2 expression in wild type C57Bl6 MFBs.

Figure 5- A.) and B.) 5×10^6 rat MFBs were electroporated as outlined “Materials and methods”. 2µgs control siRNA or siRNA designed to target rat EZH2 was used per transfection. Total RNA was prepared from control or rat EZH2 siRNA transfected cells 48h after the electroporation. First strand cDNA was synthesised which was then utilised as a template in qPCR using primers for specific amplification of EZH2 (in A.) and PPARγ (in B.). C.) Fully differentiated MFBs were treated with 1µM 3-deazaneplanocin A or vehicle for 72h at which time total RNA was prepared from control or drug treated cells. First strand cDNA was synthesised which was then utilised as a template in qPCR using primers for specific amplification of PPARγ. **D.)** Freshly isolated rat HSC were plated out onto plastic in two separate dishes and one dish treated with 1µM 3-deazaneplanocin A at 12h following the HSC isolation. Photomicrographs were taken of control and 3-deazaneplanocin A treated dishes after 10 days of culturing. **E.)** RNA was isolated from a small piece of frozen CCl₄ injured C57Bl6 mouse livers from mice pre-treated with 3-deazaneplanocin A or vehicle. First strand cDNA was synthesised which was then utilised as a template in qPCR using primers for specific amplification of mouse collagen I and TIMP1. Each data point is an average of results obtained from 4 mice. Results are expressed as percent control of 3-deazaneplanocin A and olive oil vehicle injected mice (data not included in the graph). 5F- shows that administration of the EZH2 inhibitor to mice during acute liver injury with carbon tetrachloride also suppressed the induction of transcripts for α1(I) collagen and TIMP-1

which are accurate surrogate markers for the *in vivo* MTD of hepatic stellate cells and the hepatic wound-healing response.

Figures 6 and 7 shows exons A1 and A2 of the PPAR γ gene which are spanned by a methylated CpG island.

Figure 8. To rule out a possibility that MeCP2 hemizyosity was simply attenuating hepatocellular damage caused by CCl₄, plasma ALT levels were measured as a standard parameter of liver injury. As the ALT levels were similar between Wt and *Mecp2*^{-y} mice and hepatic MeCP2 expression is selective for myofibroblasts, the inventors conclude that deletion of MeCP2 protects against fibrosis due to the loss of its influence on MTD and wound-healing.

Figure 9 shows a novel epigenetic relay pathway that is triggered by loss of miR132 expression, leading to subsequent activation of MeCP2, histone lysine methylation events (H3K9 and H3K27) and recruitment of transcriptional repressors such as HP1 α .

Figures 10A and 10B shows the photographs of cells growing in presence of several compounds (Table 1) which were taken on day 4 (early MTD) and day 7 (full MTD). These results show that several drugs of Table 1 hereof prevent/inhibit morphological changes associated with MTD.

Figure 11 shows that several drugs of Table 1 hereof inhibit fibrogenic activity of the cells as measured by production of collagen I.

Detailed Description of the Invention

The following terms shall be used to describe the present invention. In instances where a term is not specifically defined herein, the definition given to that term is that which is used within the context of the present invention by those of ordinary skill in the art.

“Patient” or “subject” refers to an animal, preferably a mammal, even more preferably a human, in need of treatment or therapy to which compounds according to the present invention are administered in order to inhibit fibrogenesis, including liver fibrogenesis, or

treat a fibrotic disease or a condition or disease state which occurs secondary or as a consequence of fibrogenesis and is treatable using compounds according to the present invention.

The terms “fibrogenesis” and “fibrosis” are used synonymously throughout the specification to describe the process of forming or developing excess fibrous connective tissue in an organ or tissue as a reparative or reactive process, as opposed to a formation of fibrous tissue as a normal constituent of an organ or tissue. Fibrogenesis is the process of forming fibrous tissue usually by degeneration (e.g., fibrosis of the pulp) and a proliferation of fibroblasts. Fibrogenesis is an abnormal condition in which fibrous connective tissue spreads over or replaces normal smooth muscle or other normal organ tissue. Fibrogenesis is most common in the heart, lung, peritoneum, and kidney, but may occur elsewhere. In the present invention, the term “fibrosis” is used to distinguish abnormal from normal healing processes. There are a number of disease states or conditions which are caused by fibrogenesis including for example, liver (alcoholic, viral, autoimmune, metabolic and hereditary), renal (chronic inflammation, infection, type II diabetes) lung fibrosis (idiopathic or resulting from environmental insults including toxic particles, sarcoidosis, asbestosis, hypersensitivity pneumonitis, bacterial infections including tuberculosis, medicines, etc.) and pancreatic fibrosis (alcohol abuse, chronic inflammatory disease of the liver), systemic scleroderma (autoimmune disease resulting in fibrosis in numerous organs), macular degeneration, cardiac fibrosis, cystic fibrosis of the pancreas and lungs, injection fibrosis, which can occur as a complication of intramuscular injections, especially in children, endomyocardial fibrosis, systemic idiopathic fibrosis, idiopathic pulmonary fibrosis (lung), mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis (which is a complication of coal worker’s pneumoconiosis), nephrogenic systemic fibrosis, nodular subepidermal fibrosis (e.g, benign fibrous histiocytoma, pleural fibrosis, fibrosis as a consequence of surgery (e.g., surgical implants), proliferative fibrosis, pipestem fibrosis, postfibrinous fibrosis, bridging fibrosis, and radiation fibrosis, among others.

Disease states or conditions which are found or occur secondary to fibrosis include for example, cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome and rheumatoid arthritis, among others.


The term “compound” is used herein to refer to any specific chemical compound disclosed herein, including compounds which are conjugated to mono and/or polyclonal antibodies to MeCP₂ and/or EZH₂. Within its use in context, the term generally refers to a single compound, but in certain instances may also refer to stereoisomers and other positional isomers and/or optical isomers (including racemic mixtures) of disclosed compounds. The compounds of this invention include all stereoisomers where relevant (e.g., cis and trans isomers, such as of vinyl groups) and all optical isomers of the present compounds (eg., R and S enantiomers), as well as racemic, diastereomeric and other mixtures of such isomers, as well as all polymorphs and hydrates of the present compounds, where applicable. Note that a dashed line ----- which represents a bond between two atoms in a compound signifies that the bond may be a single bond or a double bond in context, depending upon the substituents (if any) on the atoms to which the dashed line is attached. By way of example, in exemplary purine compounds according to the invention, where G is an oxygen atom (O), the bond between O and the carbon atom to which it is attached is a double bond and the bond between the carbon to which the oxygen is bonded and the alpha nitrogen is a single bond, and E (which is bonded to the nitrogen atom alpha to the carbon) is H. When G is a NR^{1a}R² group, then the bond between NR^{1a}R² and the carbon atom to which it is attached is a single bond and the bond between the carbon to which the nitrogen of NR^{1a}R² is bonded and the alpha nitrogen is a double bond, and E (which is bonded to the nitrogen atom alpha to the carbon) is non-existent.

“Hydrocarbon” or “hydrocarbyl” refers to any monovalent radical containing carbon and hydrogen, which may be straight, branch-chained or cyclic in nature. Hydrocarbons include linear, branched and cyclic hydrocarbons, including alkyl groups, alkylene groups, saturated and unsaturated hydrocarbon groups, including aromatic groups both substituted and unsubstituted.

“Alkyl” refers to a fully saturated monovalent radical containing carbon and hydrogen, and which may be cyclic, branched or a straight chain. Examples of alkyl groups are methyl, ethyl, n-butyl, n-hexyl, n-heptyl, n-octyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl. Preferred alkyl groups are C₁-C₂₀ alkyl groups, more preferably C₁-C₆ alkyl groups. “Alkylene” refers to a fully saturated hydrocarbon which is divalent (may be linear, branched or cyclic) and which is optionally substituted. The term “ether” shall mean a C₁ to

C₂₀ ether group, formed from an oxygen and an alkyl group at a position on the sugar moiety of compounds according to the present invention, or alternatively, may also contain at least one oxygen group within the alkyl chain.

The term “acyl” is used throughout the specification to describe a group on a free amine or hydroxyl position (e.g., in the carbocyclic moiety or the nucleoside base) which contains a C₁ to C₂₀ linear, branched or cyclic alkyl chain. The acyl group at the 5' position, in combination with the 5' hydroxyl group results in an ester, which, after administration, may be cleaved to produce the free nucleoside form of the present invention. Acyl groups according to the present invention are represented by the structure:




where R⁴ is a C₁ to C₂₀ linear, branched or cyclic alkyl group, alkoxyalkyl (including an ethylene oxide chain which may end in a free hydroxyl group or a C₁-C₁₀ alkyl group and ranges in molecular weight from about 50 to about 40,000 or about 200 to about 5,000), such as phoxymethyl, aryl, alkoxy, alkoxyalkoxy groups (e.g., [(isopropoxycarbonyl)oxy]-methoxy), aryloxyalkyl, among others, all of which groups may be optionally substituted. Preferred acyl groups are those where R⁴ is a C₁ to C₁₀ alkyl group. Acyl groups according to the present invention also include, for example, those acyl groups derived from benzoic acid and related acids, 3-chlorobenzoic acid, succinic, capric and caproic, lauric, myristic, palmitic, stearic and oleic groups, among numerous others and may include such related groups as sulfone groups such as mesylate groups. All groups may be appropriately substituted within context as otherwise described herein. One of ordinary skill in the art will recognize the acyl groups which will have utility in the present invention, either to synthesize the target pharmaceutical compounds or as prodrug of the nucleosides according to the present invention.

The term “amino acid” or “amino acid residue” shall mean, within context, a radical of a D- or L-amino acid which is covalently bound to a nucleoside analog at the 4' exocyclic amine position of the cytosine base or the 5'- or 3'-OH position of the sugar synthon (R², R¹ or R^{1a}) through a carboxylic acid moiety of the amino acid, thus forming respectively, an amide or ester group linking the nucleoside to the amino acid. Representative amino acids

include both natural and unnatural amino acids, preferably including, for example, alanine, β -alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine, among others.

The term “phosphate ester” or “phosphodiester” is used throughout the specification to describe mono-phosphate groups at the 5' position of the carboyclic sugar synthon which are mono- or diesterified such that the phosphate group is negatively charged or is rendered neutral, i.e., has a neutral charge. Phosphate esters for use in the present invention include those represented by the structures:



where each R^5 , R^6 and R'' is independently selected from H, a C_1 to C_{20} linear, branched or cyclic alkyl group, alkoxyalkyl, aryloxyalkyl, such as phenoxymethyl, aryl and alkoxy, among others, including alkoxycarbonyloxy groups (e.g., (isopropoxycarbonyl)oxy]-methoxy) with the proviso that at least one R^5 group is other than H, or the two R^5 groups together form a five- or six-membered heterocyclic group, B is a direct bond (N directly bonded to C of the ester/carboxylic acid group) or a C_1 - C_3 alkylene group optionally substituted with a C_1 - C_3 alkyl group, preferably a methyl group and R^7 is a C_1 to C_{20} linear, branched or cyclic alkyl or acyl group, alkoxyalkyl, aryloxyalkyl, such as phenoxymethyl, aryl and alkoxy, among others, each of which groups previously mentioned may be optionally substituted. Preferred monophosphate esters for use in prodrug forms according to the present invention are those where R^5 is a C_1 to C_{20} linear or branched chain alkyl group, more preferably a C_1 to C_3 alkyl group, all of which groups may be optionally substituted.

Other terms used to indicate substituent groups in compounds according to the present invention are as conventionally used in the art.

"Aryl" or "aromatic" refers to a substituted or unsubstituted monovalent aromatic radical having a single ring (*e.g.*, benzene) or multiple condensed rings (*e.g.*, naphthyl, anthracenyl, phenanthryl), which may be optionally substituted and can be bound to the compound according to the present invention at any position on the ring(s) (preferably, for example, benzyl).

The term "cyclic" shall refer to an optionally substituted carbocyclic or heterocyclic group, preferably a 3-7-membered ring, preferably a 5- or 6-membered ring. A heterocyclic ring or group shall be a ring containing between 3 and 7 atoms of which up to four of those atoms are other than carbon and are selected from nitrogen, sulfur and oxygen. Carbocyclic and heterocyclic rings according to the present invention may be unsaturated or saturated.

The term "effective" or "effective amount" refers to the amount of a selected compound which is effective within the context of its use or administration. In the case of therapeutic methods according to the present invention, the precise amount required will vary depending upon the particular compound selected, the age and weight of the subject, route of administration, and so forth, but may be easily determined by routine experimentation. Compounds according to the present invention may be used to treat, inhibit or reduce the likelihood of fibrosis, fibrotic disease and/or conditions or disease states which occur secondary to fibrosis, as well as reducing the likelihood of viral infections (by for example, inhibition the growth, replication or elaboration of the virus).

The term "substituted" shall mean substituted at a carbon (or nitrogen) position with, in context, hydroxyl, carboxyl, cyano ($C\equiv N$), nitro (NO_2), halogen (preferably, 1, 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifluoromethyl), thiol, alkyl group (preferably, C_1 - C_6 , more preferably, C_1 - C_3), alkoxy group (preferably, C_1 - C_6 alkyl or aryl, including phenyl), ester (preferably, C_1 - C_6 alkyl or aryl) including alkylene ester (such that attachment is on the alkylene group, rather than at the ester function which is preferably substituted with a C_1 - C_6 alkyl or aryl group), thioether (preferably, C_1 - C_6 alkyl or aryl), thioester (preferably, C_1 - C_6 alkyl or aryl), (preferably, C_1 - C_6 alkyl or aryl), halogen (F,

Cl, Br, I), nitro or amine (including a five- or six-membered cyclic alkylene amine, including a C₁-C₆ alkyl amine or C₁-C₆ dialkyl amine), alkanol (preferably, C₁-C₆ alkyl or aryl), or alkanolic acid (preferably, C₁-C₆ alkyl or aryl). Preferably, the term “substituted” shall mean within its context of use alkyl, alkoxy, halogen, hydroxyl, carboxylic acid, nitro and amine (including mono- or di- alkyl substituted amines). The term unsubstituted shall mean substituted with one or more H atoms.

The term “virus” shall be used to describe all types of viruses which produce fibrogenesis, including liver fibrogenesis and/or cause or exacerbate cirrhosis of the liver, as well as other disease states or conditions which occur secondary to fibrogenesis.

The term “enantiomerically enriched” or “ee” is used throughout the specification to describe a nucleoside which includes at least about 95%, preferably at least about 96%, more preferably at least about 97%, even more preferably, at least about 98%, and even more preferably at least about 100% or more of a single enantiomer of that nucleoside. Compounds according to the present invention are generally β-D-nucleoside compounds. When the present compounds according to the present invention are referred to in this specification, it is presumed that the nucleosides have the D-nucleoside configuration and are enantiomerically enriched (preferably, about 100% of the D-nucleoside), unless otherwise stated.

The terms “coadminister” and “coadministration” are used synonymously to describe the administration of at least one of the nucleoside compounds and/or antibodies according to the present invention in combination with at least one other agent. While it is preferred that coadministered agents be administered at the same time, agents may be administered at times such that effective concentrations of both (or more) agents appear in the patient at the same time for at least a brief period of time.

The term “independently” is used herein to indicate that the variable, which is independently applied, varies independently from application to application.

Compounds according to the present invention may be used in pharmaceutical compositions having biological/pharmacological activity for the treatment, inhibition or reducing the likelihood of fibrogenesis, including liver fibrogenesis and other forms of

fibrogenesis or fibrotic disease, as well as a number of other conditions and/or disease states which may appear or occur secondary to fibrogenesis, as otherwise described herein. These compositions comprise an effective amount of any one or more of the compounds disclosed hereinabove, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient. In addition, compounds according to the present invention may be used to inhibit methylation of polynucleotides, in particular, DNA and RNA in numerous tissue and cells in a patient, including liver cells. While not be limited by way of theory, it is believed that this mechanism is responsible, at least in part, for the activity shown by compounds in inhibiting fibrogenesis, including liver fibrogenesis and/or in treating cirrhosis of the liver, as well as numerous other fibrotic diseases and/or disease states or conditions which occur secondary to fibrogenesis. Compounds according to the present invention may also be used as intermediates in the synthesis of compounds exhibiting biological activity as well as standards for determining the biological activity of the present compounds as well as other biologically active compounds.

The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously. Administration will also be depend upon the tissue in which fibrogenesis and/or related disease states or conditions occur.

Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension, especially when an antibody is used alone or conjugated to a nucleoside compound disclosed herein. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye (especially macular degeneration), the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these

areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

The amount of novel nucleoside of the instant invention that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of at least about 0.005 mg/kg, between about 0.01 and 150 mg/kg, preferably about 0.5 to about 25 mg/kg of patient/day of the nucleoside according to the present

invention can be administered to a patient receiving these compositions.

It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease or condition being treated.

Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration. Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient. Oral dosage forms are particularly preferred, because of ease of administration and prospective favorable patient compliance.

To prepare the pharmaceutical compositions according to the present invention, a therapeutically effective amount of one or more of the compounds according to the present invention is preferably intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques to produce a dose. A carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral. In preparing pharmaceutical compositions in oral dosage form, any of the usual pharmaceutical media may be used. Thus, for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives including water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents and the like may be used. For solid oral preparations such as powders, tablets, capsules, and for solid preparations such as suppositories, suitable carriers and additives including starches, sugar carriers, such as dextrose, mannitol, lactose and related carriers, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used. If desired, the tablets or capsules may be enteric-coated or sustained release by standard techniques. The use of these dosage forms may significantly the bioavailability of the compounds in the patient.

For parenteral formulations, the carrier will usually comprise sterile water or aqueous sodium chloride solution, though other ingredients, including those which aid dispersion, also may be included. Of course, where sterile water is to be used and maintained as sterile, the compositions and carriers must also be sterilized. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.

Liposomal suspensions (including liposomes targeted to viral antigens) may also be prepared by conventional methods to produce pharmaceutically acceptable carriers. This may be appropriate for the delivery of free nucleosides, acyl/alkyl nucleosides or phosphate ester pro-drug forms of the nucleoside compounds according to the present invention.

In particularly preferred embodiments according to the present invention, the compounds and compositions are used to inhibit fibrogenesis (fibrosis) as otherwise described herein, especially liver fibrogenesis, or to treat, prevent or delay the onset of cirrhosis. Preferably, to treat, prevent or delay the onset of cirrhosis, the compositions will be administered in oral dosage form in amounts ranging from about 250 micrograms up to about 500 mg or more at least once a day, preferably, up to four times a day, within the dosage range used for therapeutic treatment. The present compounds are preferably administered orally, but may be administered parenterally, topically, in suppository or other form.

In addition, compounds according to the present invention may be administered alone or in combination with other agents, including other compounds of the present invention. Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.

As indicated, compounds according to the present invention may be administered alone or in combination with other agents for the treatment of liver fibrogenesis and/or cirrhosis of the liver in an individual to be treated. Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents

according to the present invention by reducing the metabolism or inactivation of other compounds and as such, are co-administered for this intended effect.

The present invention is now described, purely by way of illustration, in the following further description and the attached examples. It will be understood by one of ordinary skill in the art that these examples are in no way limiting and that variations of detail can be made without departing from the spirit and scope of the present invention.

The hepatic stellate cell occupies the space between hepatocytes on one side and endothelial cells and the hepatic sinusoid on the other side. This location enables the hepatic stellate cell to be a sensor for hepatocyte and endothelial cell damage, inflammation and microbial products from the bloodstream (Frideman SL, 2008). Hepatic stellate cells therefore provide a mechanism for activation of a rapid innate wound-healing response to environmental insults. The vast number of changes in gene expression that underpin MTD suggests an extensive reprogramming of the cellular epigenome is required in order to suppress the adipogenic features of the quiescent hepatic stellate cell in favour of the acquisition of the myofibroblast phenotype (De Minicis S *et al* 2007, She H *et al* 2005, Tsukamoto H *et al* 2006). It is critical that this epigenome reprogramming is under tight regulation since inappropriate MTD would lead to the formation of unwanted scar tissue and promote the development of fibrosis (Friedman SL, 2008). The regulatory mechanisms that orchestrate the changes in gene expression during MTD remain poorly defined.

PPAR γ expression is associated with the adipogenic features of the quiescent hepatic stellate cell and must be silenced for the cell to adopt its myofibroblastic characteristics including entry to the cell cycle and expression of the major protein constituent of scar tissue, type I collagen (She H *et al* 2005, Tsukamoto H *et al* 2006). Forced over-expression of PPAR γ in hepatic myofibroblasts results in reversion of MTD with down-regulation of type I collagen, loss of proliferation and reacquisition of their adipogenic characteristics. Given the pivotal regulatory role played by PPAR γ in MTD, we reasoned that investigation of its transcriptional regulation in hepatic stellate cells would lead to the discovery of novel and critical regulators of MTD and wound-healing.

The *in vitro* culture of freshly isolated primary hepatic stellate cells provides a widely accepted model that recapitulates the majority of phenotypic changes observed for MTD in

the injured liver (Friedman SL 2008, De Minicis S *et al* 2007). In this model, freshly isolated hepatic stellate cells are cultured on plastic in serum-containing media and over a period of roughly 7 days undergo a step-wise transformation into a myofibroblastic phenotype. Culture-induced MTD of hepatic stellate cells is associated with a greater than 95% loss of PPAR γ transcript (Fig 1A) and as determined by cross-linked ChIP, depletion of elongating RNA polymerase II (P-Ser²-RNAP) at the PPAR γ gene (Fig 1B). This coincided with recruitment of the methyl-CpG binding protein MeCP2 to the promoter and exons A1 and A2 of the PPAR γ gene (Fig 1C) which are spanned by a methylated CpG island (Figs 6 and 7). Since MeCP2 is a powerful epigenetic repressor of gene transcription we investigated the possibility that it controls silencing of PPAR γ expression during MTD (Chadwick and Wade 2007). siRNA knockdown of MeCP2 in myofibroblasts (Fig 1D) resulted in elevated PPAR γ transcript expression (Fig 1E), furthermore a 5-fold increased expression of PPAR γ mRNA was observed in MeCP2 deficient *Mecp2*^{-/-} mouse myofibroblasts compared with wild type (Wt) myofibroblasts (Fig 1F). MeCP2 expression is barely detectable in the normal liver but is induced selectively in myofibroblasts of the injured liver (Mann *et al*, 2007). To investigate a wound-healing role for MeCP2 *in vivo* we compared hepatic PPAR γ expression between Wt and *Mecp2*^{-/-} mice that had been repeatedly injured with the hepatotoxin carbon tetrachloride (CCl₄) which causes chronic hepatic wound-healing/fibrogenesis (Iredale JP JCI 2007). Absence of hepatic MeCP2 (Fig 2A) resulted in higher PPAR γ mRNA expression in the injured liver (Fig 2B). PPAR γ is a negative regulator of the expression of type I collagen, the major fibrogenic collagen produced by myofibroblasts in response to injury (Yavrom *et al*, 2005). Expression of hepatic type I collagen was reduced by 90% in injured *Mecp2*^{-/-} mice compared to Wt (Fig 2C). Sirius red staining of injured Wt livers detected tracts of fibrotic collagen-rich matrix that formed bridges between hepatic vessels (Fig 2D, left). In contrast, bridging fibrosis was not evident in injured *Mecp2*^{-/-} livers, although thin tracts of fibrotic matrix were visible around vessels and within the spaces between hepatic parenchyma (Fig 2D right). Blinded histopathology grading for fibrosis (on the Metavir scale of 0 for normal to 4 for cirrhosis) confirmed reduced wound-healing/fibrogenesis in *Mecp2*^{-/-} livers with a score of grade 1 (mild fibrosis) compared with grade 3 (severe bridging fibrosis) for wild type. To rule out a possibility that MeCP2 hemizyosity was simply attenuating hepatocellular damage caused by CCl₄, we measured plasma ALT levels as a standard parameter of liver injury. As the ALT levels were similar between Wt and *Mecp2*^{-/-} mice (Fig. 8) and hepatic MeCP2 expression is selective for myofibroblasts, we conclude that deletion of MeCP2 protects against fibrosis due to the loss of its influence on MTD and wound-healing. Forced

over-expression of PPAR γ in hepatic myofibroblasts protects against development of fibrosis (Hazra S *et al* 2004, Tsukamoto H *et al* 2006). The attenuated fibrogenic response of the *Mecp2*^{0/0} mouse is therefore explained, at least in part, by maintenance of PPAR γ expression. However, we have previously reported that MeCP2 is also required for repression of I κ B α expression during MTD of hepatic stellate cells, this being critical for the expression of NF- κ B-dependent genes in the myofibroblast (Mann J *et al*, 2007). MeCP2 is therefore likely to operate during MTD as a coordinator of the transcriptional silencing of multiple genes associated with the quiescent phenotype of the hepatic stellate cell.

As MeCP2 is important for MTD and wound-healing we were next interested to determine how its expression is controlled in hepatic stellate cells. MeCP2 protein is undetectable in hepatic stellate cells but is strongly induced with MTD (Mann J *et al*, 2007). Here we show that MeCP2 protein expression is induced during the early transitional phase (day 1) of culture-induced MTD and increases in expression with each subsequent day of culture, reaching high levels when the cells have fully transdifferentiated to the myofibroblastic state (day 7). This early induction of MeCP2 supports a regulatory role for MeCP2 in transdifferentiation (fig 3A). However, MeCP2 transcript was detected prior to MTD indicating post-transcriptional regulation (fig 3B). The *Mecp2* gene contains multiple polyadenylation sites and generates several transcripts which differ in their length of 3' UTR, ranging from 1.8kb to 10kb (Klein *et al* 1007). The 10kb transcript predominates in the brain and unlike the shorter transcripts harbours recognition elements for several miRNAs including miR132 which is also enriched in the brain. As hepatic stellate cells express various neuronal characteristics (e.g. expression of synaptophysin, serotonin receptors and N-cadherin) we reasoned that they may also express the 10kb transcript of *Mecp2* and miR132. Primers located between 1 and 8.5kb from the translational stop codon of the MeCP2 transcript were employed for RT-PCR detection of short versus long transcript. This analysis showed that hepatic stellate cells express the elongated form of MeCP2 transcript inclusive of the miR132 binding site (Fig 3C). MTD is accompanied by a greater than 90% diminution of miR132 suggesting a dramatic reduction in miR132 activities in myofibroblasts compared with quiescent hepatic stellate cells (Fig 3D). Transfection of miR132 increased expression of the micro RNA in myofibroblasts by 300 fold (Fig 3E) which was associated with diminished expression of MeCP2 protein (Fig 3F). This treatment was also accompanied by increased PPAR γ mRNA expression (Fig 3G). We conclude that MeCP2, and in turn MTD, are under the negative regulation of miR132 in quiescent hepatic stellate cells. Klein *et al* reported that

during neuronal differentiation miR132 is induced via a CREB-dependent pathway involving CREB phosphorylation (Klein ME *et al* 2007). Of note, induction of CREB phosphorylation has previously been described to suppress fibrogenic characteristics of hepatic stellate cell-derived myofibroblasts (Houglum K *et al*, 1997). It therefore seems likely that CREB phosphorylation suppresses MTD via induction of miR132.

The inventors were next interested to determine the downstream regulatory events through which MeCP2 controls PPAR γ transcription. High resolution quantitative native ChIP was employed to detect MeCP2-dependent histone methylation signatures at the PPAR γ locus (Fig 3H). Repressive signatures H3K9me2 and H3K27me2 were enriched at the gene in wild type myofibroblasts, however both of these modifications were depleted in *Mecp2*^{-/-} myofibroblasts. By contrast the transcriptional active signature H3K4me2 was almost absent in wild type myofibroblasts but was highly enriched in *Mecp2*^{-/-} cells. MeCP2 must therefore orchestrate multiple epigenetic events at the PPAR γ chromatin. It has been previously reported that MeCP2 facilitates H3K9 methylation and that this repressive mark recruits the transcriptional repressor HP1 α (Fuks *et al*, 2003). ChIP analysis confirmed that HP1 α is recruited selectively to the promoter and exons A1 and A2 of the PPAR γ gene (Fig 4A) which coincides with the binding pattern for MeCP2 shown in Fig 1C. Since HP1 α is selectively recruited to the 5' region of the PPAR γ gene in myofibroblasts and is absent from the gene in quiescent hepatic stellate cells, we conclude that MeCP2-dependent methylation of H3K9 recruits HP1 α . Although HP1 α is predominantly associated with heterochromatic DNA it is also found at euchromatic sites in association with transcriptionally repressed genes where it promotes a repressive chromatin structure (Cheutin T *et al* 2003). Hence one mechanism by which MeCP2 regulates transcriptional silencing of PPAR γ during MTD of hepatic stellate cells is the recruitment of HP1 α to methylated H3K9 at the 5' region of the PPAR γ gene.

The observation that methylation of H3K27 was depleted in *Mecp2*^{-/-} myofibroblasts was of interest as to date there is no known association between MeCP2 and this histone modification. ChIP analysis showed that H3K27 methylation (H3K27me2) is barely detected at the PPAR γ gene in quiescent hepatic stellate cells but is enriched at exons 1 to 5 in myofibroblasts (Fig 4B). As exons 1 to 5 are downstream of the sites at which MeCP2 is recruited (Fig 1C), MeCP2 is unlikely to be directly responsible for H3K27 methylation but may instead regulate this modification through an indirect mechanism. Methylation of

H3K27 is specifically mediated by the evolutionary conserved polycomb repressor complex 2 (PRC2) and in particular by its constituent H3K27 methyl-transferase EZH2 (Kirmizis *et al*, 2004, Schotta *et al*, 2004). EZH2 protein expression is absent in quiescent hepatic stellate cells and is induced with MTD, but later (day 3 of culture) than observed for MeCP2 (Fig 4C). Cells depleted of MeCP2 by siRNA treatment expressed lower levels of EZH2 compared with control cultures (Fig 4D). We also measured 60% lower EZH2 transcript expression in *Mecp2*^{-/-} myofibroblasts compared with wild type cells. These results reveal an unexpected role for MeCP2 as a positive regulator of EZH2 expression and provide an explanation of how MeCP2 is able to stimulate H3K27 methylation. While MeCP2 is classically considered to be a transcriptional repressor, it has recently emerged from studies with neurons that it can also function as an activator of transcription for a subset of genes including somatostatin, opioid receptor kappa 1, guanidinoacetate methyltransferase and G protein-regulated inducer of neurite outgrowth 1 (Chahnkour M *et al* 2008).

To provide direct evidence that EZH2 is a regulator of PPAR γ gene transcription the inventors employed siRNA-mediated knockdown to achieve an 80% depletion of EZH2 in myofibroblasts (Fig 5A) and showed that this resulted in elevated expression of PPAR γ transcript (Fig 5B). A similar effect was observed when myofibroblasts were treated with 3 deazaneplanocin A (Fig 5C) which depletes cells of EZH2 (Tan J *et al*, 2007). Furthermore, we observed that treatment of freshly isolated quiescent hepatic stellate cells with 3 deazaneplanocin A completely prevented morphological signs of MTD (Fig 5D) and suppressed the induction of fibrogenic genes α 1(I) collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) (Fig 5E). Administration of the EZH2 inhibitor to mice during acute liver injury with carbon tetrachloride also suppressed the induction of transcripts for α 1(I) collagen and TIMP-1 which are accurate surrogate markers for the *in vivo* MTD of hepatic stellate cells and the hepatic wound-healing response (Fig 5F). EZH2 is therefore a negative regulator of PPAR γ transcription in myofibroblasts, but also appears to play a wider regulatory role in promoting MTD and wound-healing. Furthermore, the stimulation of EZH2 expression and subsequent methylation of H3K27 in the downstream exons of the PPAR γ gene is identified as a second mechanism through which MeCP2 achieves transcriptional silencing of PPAR γ . The combined effect of H3K9 methylation and HP1 α binding at the 5' end of the PPAR γ gene with H3K27 methylation and PRC1 recruitment in the downstream exons would be to prevent both transcriptional initiation and elongation which reflects the biological importance of suppressing PPAR γ expression for MTD and wound-healing.

In summary, the inventors have demonstrated that MTD and in turn wound-healing are subject to tight regulatory control at the epigenetic level involving orchestrators of chromatin modifications associated with gene transcription. More specifically by focusing on the transcriptional silencing of PPAR γ during MTD we have discovered a novel epigenetic relay pathway (Fig 9) that is triggered by loss of miR132 expression, leading to subsequent activation of MeCP2, histone lysine methylation events (H3K9 and H3K27) and recruitment of transcriptional repressors such as HP1 α .

Future studies on the role of miR132, MeCP2 and EZH2 are warranted as these factors may provide further insights into the regulation of wound-healing and they may offer interesting targets for the therapeutic correction of inappropriate or unregulated wound-healing and fibrosis. For example, delivery of miR132 or the EZH2 inhibitor 3 deazaneplanocin A to hepatic myofibroblasts using emerging targeting strategies for these cells may be beneficial and can be tested in appropriate animal models (Douglass A *et al*, 2008, Hagens WI *et al* 2008). Finally, fibrosis is a common but not a universal consequence of chronic liver injury and infection, for example only 20% of patients with alcoholic liver disease progress to fibrosis. While highly speculative, it is possible that differences in the epigenome of individuals that reflect altered activities in molecules such as miR132, MeCP2 and EZH2 impact on the control of MTD and wound-healing which then determines disease outcome. Future studies in human liver disease with these molecules would therefore be highly appropriate.

Materials and Methods

Chronic CCl₄ liver injury model - Liver fibrosis was generated by 3-week CCl₄ treatment of 6 week old *Mecp2*^{-/-} hemizygote mice or age matched C57Bl6 wild type control littermates.

The mice were injected intraperitoneally twice weekly with a mixture of CCl₄/olive oil in a 1:1[vol/vol] ratio at 1 μ l per g body weight. Twenty four hours after the final CCl₄ administration, animals were sacrificed and liver samples prepared.

Acute CCL₄ liver injury- 3 deazaneplanocin A was given to two groups of four C57Bl6 mice (15mg/m² which was calculated to be 0.428 μ g of drug per g body weight of a mouse) was given IP 2 hours prior to a single dose of CCl₄ (CCl₄/olive oil in a 1:1[vol/vol] ratio at 1 μ l per

g body weight). Mice were then sacrificed 24 h after the CCl₄ injury, bloods taken for assessment of liver enzyme levels and tissues harvested for histological and biochemical analysis.

Cell isolation and culture- Rat HSC were isolated from normal livers of 350-g Sprague-Dawley rats by sequential perfusion with collagenase and Pronase, followed by discontinuous density centrifugation in 11.5% Optiprep (Invitrogen). Mouse HSCs were isolated from C57Bl6 wild type or *Mecp2*^{-/-} livers as previously described (Oakley F *et al* 2005). Rat and mouse HSCs were cultured on plastic in Dulbecco's modified Eagle's medium, supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 16% fetal calf serum. Cell cultures were maintained at 37°C at an atmosphere of 5% CO₂.

Immunohistochemistry – Mouse liver tissue was fixed in 10% formalin in phosphate-buffered saline (PBS), and liver sections stained with Sirius Red as previously described (Wright MC *et al* 2001).

siRNA transfection- Rat MFB were transfected with siRNA designed to silence either rat EZH2 (catalogue numbers s131300 and s131299) or MeCP2 (catalogue numbers s161752 and s161754) or negative control siRNA (catalogue number 4390844, all from Ambion). siRNAs were transfected into 5x10⁶ rat MFB using a square wave electroporator BTX830 (Harvard Apparatus) set at 225V to deliver 3 pulses of 10ms. Briefly, MFBs were trypsinised, washed once and resuspended in 700µl serum free media. Cells were mixed with a total of 2µg siRNA in a 4mm diameter electroporation cuvette at room temperature and current applied. The cells were allowed to grow for 48h post transfection when they were harvested and RNA and/or whole cell extracts made.

Micro RNA detection, amplification and transfection- Micro RNAs were isolated from quiescent rat HSCs and MFBs using miRNeasy mini kit (Qiagen, cat number 217004). Obtained total RNA was reverse transcribed using miScript Reverse Transcription Kit as per manufacturer's instructions. Rat miR132 in the samples was detected using miScript primer assay 218300 (Qiagen, catalogue number MS00000357). To assess the effect of miR132 presence in MFBs, miR132 mimic was purchased from Qiagen (miScript miRNA mimic 219600-S0, catalogue number MSY0000838) and 2µg were transfected into 5x10⁶ MFBs as

outlined for siRNA transfections, except for electroporator settings which were 500V for 1ms delivered as a single pulse.

SDS-PAGE and Immunoblotting - Whole cell extracts were prepared, and protein concentration of samples determined using a Bradford DC assay kit (Bio-Rad). Whole cell extracts from samples of interest were then fractionated by electrophoresis through a 9% SDS-polyacrylamide gel. Gels were run at a 100 V for 1.5 hours before transfer onto nitrocellulose. After blockade of nonspecific protein binding, nitrocellulose blots were incubated for 1 hour with primary antibodies diluted in Tris-buffered saline (TBS)/Tween 20 (0.075%) containing 5% bovine serum albumin (BSA). Rabbit polyclonal antibody recognizing MeCP2 (ab-2828, Abcam) was used at 1µg/ml; EZH2 at 1/500 dilution (Active Motif, catalogue number 39103) and β actin at 1/1000 dilution (Sigma). Following incubation with primary antibodies, blots were washed three times in TBS/Tween 20 before incubation for 1 hour in appropriate HRP-conjugated secondary antibody. After extensive washing in TBS/Tween 20, the blots were processed with distilled water for detection of antigen using the enhanced chemiluminescence system (Amersham Biosciences).

Quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) - Total RNA was purified from isolated cells using the Total RNA purification kit (Qiagen, UK) following the manufacturer's instructions and was used to generate first strand cDNA utilising a random hexamer primer [p(dN)6] and MMLV reverse transcriptase. Primers for rat PPAR γ were 5'-atttctgctccacactat -3' (sense) and 5'-gctttatccccacagact -3' (anti-sense); EZH2 were 5'-agtggagtgggtgctgaag -3' (sense) and 5'-gccgtccttttcagttg -3' (anti-sense); mouse PPAR γ were 5'-aagagctgacccaatggt -3' (sense) and 5'-atggttcttcggaaaaa -3' (anti-sense); rat β actin were 5'-agagggaatcgtgcgtgaca -3' (sense) and 5'-acatctgctggaaggtggaca -3' (anti-sense); rat MeCP2 were 5'-ttgaaaaggtgggagaca -3' (sense) and 5'-tgctgctgcctttggtct -3' (anti-sense); collagen I were 5'-ttc acc tac agc acg ctt gtg-3' (sense) and 5'-gat gac tgt ctt gcc cca agt t-3' (antisense) and TIMP1 were 5'-gca tgg aca ttt att ctc cac tgt-3' (sense) and 5'-tct cta gga gcc ccg atc tg-3' (antisense). Real-time PCR analysis was performed on an ABI 7500HT sequence detection system. In brief, qPCR reactions comprised of 20ng of cDNA template, 15 pmoles each of sense and anti-sense oligonucleotide primers and 6.5µl of Jumpstart SYBR green master mix (Sigma) in a total reaction volume of 13µl. After the initial 20sec incubation at 94°C, qPCRs were performed using a 20sec annealing at 55°C followed by a

30sec elongation step at 72°C and a 5sec denaturation step at 94°C. After each run, a dissociation curve was performed to ensure that no primer dimers contaminated the quantification and that the product had the expected melting temperature. All PCR reactions were normalized to the internal control and relative level of transcriptional difference calculated using the following equation: $[1/(2A)] \times 100$.

3'UTR of MeCP2 analysis- Long 3' UTR of MeCP2 mRNA was detected using a number of primer pairs which were designed to specifically detect regions of long 3'UTR that were starting at positions 989bp (MeCP2 3UTR 1), 1978bp (MeCP2 3UTR 2), 4063bp (MeCP2 3UTR 3), 5162bp (MeCP2 3UTR 4), 6868bp (MeCP2 3UTR 5) and 8401bp (MeCP2 3UTR 6) after the stop codon. The primers were: for MeCP2 3UTR 2 were 5'-tcattatgggtatatccttttctgtgtt-3' (sense) and 5'-ttgacagttcatggcagcag-3' (antisense); MeCP2 3UTR 3 were 5'-ctctgccttgagcagcaggtt-3' (sense) and 5'-cagcgaaagataccaccata-3' (antisense); MeCP2 3UTR 4 were 5'-attctagggcggtgactga-3' (sense) and 5'-agagagcgggaagaaagagc3' (antisense); MeCP2 3UTR 5 were 5'-atgaccttgctccttgctc-3' (sense) and 5'-ggaagaacagctttgccact-3' (antisense); MeCP2 3UTR 6 were 5'-caatcaataacagacgtcca-3' (sense) and 5'-aagggaaggaagaaagagg-3' (antisense); MeCP2 3UTR 7 were 5'-aaaaacaaaaggcaattattaagga-3' (sense) and 5'-aacaaaagacacaaacggaca-3' (antisense).

Crosslinked Chromatin Immunoprecipitation (XChIP) Assay—ChIP assay was carried out using 100µg crosslinked chromatin prepared from rat HSC or MFB as described previously (Mann J *et al* 2007). Antibodies used for immunoprecipitation were raised against MeCP2, RNA polymerase II CTD repeat YSPTSPS (phospho S2) and HP1α, all purchased from Abcam. 10µg of each antibody or appropriate irrelevant antibody control were used in each ChIP reaction. ChIP primers for rat PPARγ gene were promoter or exon specific and the sequences were as follows- PPARγ promoter 5'- ttccaagtcctttccacac -3' (sense) and 5'-gagaggcatgtctctctgg -3' (anti-sense); PPARγ exon A1 was 5'- aggggactgagtgtgacgac -3' (sense) and 5'- tcacacagtcggtcagaaa -3' (anti-sense); PPARγ exon A2 was 5'-catgctcggagaaagcaaat -3' (sense) and 5'- agtgggtcacagcttcttcaa -3' (anti-sense); PPARγ exon 1 was 5'- tgaagacatcccgttcacaa -3' (sense) and 5'- cgccttctcttcagagtgt -3' (anti-sense); PPARγ exon 2 was 5'- gcacaggtgcgatcaaagta -3' (sense) and 5'- accttgcatccttcacaagc -3' (anti-sense); PPARγ exon 3 was 5'- aagaacctccgattgaagc -3' (sense) and 5'- gccaggagcgttacaagatg -3' (anti-sense); PPARγ exon 4 was 5'- gaccagctgaaccagagtc -3' (sense) and 5'-

acccaatgaagagagcaga -3' (anti-sense); PPAR γ exon 5 was 5'- tttcaagggtgccagtttc -3' (sense) and 5'- gaggccagcatggtgtagat -3' (anti-sense); PPAR γ exon 6 was 5'- cgaggacatccaagacaacc -3' (sense) and 5'- tcagcgactgggacttttct -3' (anti-sense); mouse PPAR γ promoter was 5'- ctggcgagacaatgtagcaa -3' (sense) and 5'-ttgggagaggtgggaataaa-3' (anti-sense). Each PCR reaction was performed in triplicate and the analysis was repeated twice from independent ChIP experiments. A signal intensity value for each sample was calculated from the average of the experiments. Average values of eluates were normalized to average values of inputs.

Native Chromatin Immunoprecipitation (NChIP) Assay- Native ChIP was carried out as previously described (O'Neill LP *et al* 2003) using 100 μ g native chromatin prepared from rat HSC or MFB. Antibodies raised against dimethylated forms of H3K4, H3K27 and were all purchased from Abcam.

Further Testing

The cardinal role of the smooth muscle myofibroblast in wound-healing is well established, as is the concept that persistence of myofibroblasts in chronic injury leads to a fibrotic response. Myofibroblasts are rare in uninjured tissues but are generated in response to trauma, inflammation or infection by the transdifferentiation of resident cells. In the liver, hepatic myofibroblasts are chiefly generated by transdifferentiation of perisinusoidal hepatic stellate cells (HSC). In the uninjured liver, HSCs are quiescent, retinoid storing cells with an adipogenic phenotype characterised by expression of PPAR γ , SREBP1c and adipsin. Upon liver injury, HSCs change phenotype to become a collagen I/III-expressing myofibroblast via a process referred to as myofibroblast transdifferentiation (MTD). In acute liver injury, MTD is a healthy response that ensures wound contraction and formation of a temporary collagen-rich scar. Hepatic myofibroblasts generated in the acute response are soon cleared by apoptosis which enables resolution of wound-healing and regeneration of normal hepatic tissue structure. However, when injury is iterative (such as in the chronic HCV infected liver) myofibroblasts fail to undergo apoptosis and instead expand due to proliferation and progressive rounds of MTD; this leads to expansion and spread of the fibrogenic reaction which if unchecked is the cause of cirrhosis and underlies development of 90% of primary liver cancers. Therefore, any agents that either prevent MTD or induce apoptosis in hepatic myofibroblasts are potential therapeutics for liver fibrosis.

Freshly isolated hepatic stellate cells cultured on plastic in full media spontaneously undergo MTD in a fashion that resembles in vivo events. This process involves morphological changes as well as changes in the expression of hundreds of genes including transcriptional silencing of adipogenic genes and induction of profibrogenic genes such as TIMP1, α SMA, and most importantly collagen 1 and 3. Due to a very defined presentation of morphological changes associated with biochemical change (large upregulation in collagen production) in hepatic stellate cells undergoing MTD, it is possible to monitor progression of MTD over a 7 day period. At the end of 7 days, all quiescent stellate cells in culture would have undergone MTD.

To test derivatives of 3-deazaneplanocin A (Table 1, below) in their ability to halt MTD in hepatic stellate cells, we plated out quiescent, freshly isolated cells onto tissue culture plastic. Photographs of quiescent stellate cells in culture were taken as shown and RNA isolated from some of the cells- this forms the starting point. The cultures were then either left to undergo MTD over 7 days (control cells) or were incubated with 1 μ M concentration of drugs 1-9 as set forth in Table 1, hereinbelow. Only one dose of drug was given at the start of culturing which was sufficient to exert effects over a week of cell growth. Photographs of cells growing in presence of various compounds were taken on day 4 (early MTD) and day 7 (full MTD) (Figs 10A and B). RNA was also isolated on days 4 and 7. Photographs (Figure show that drugs 1-4 prevent morphological changes associated with MTD, as well as inhibit fibrogenic activity of the cells as measured by production of collagen I (Fig 11). Compounds 5 and 8 showed significant inhibition at 7 days as evidenced by the results set forth in Fig. 11. Compound 9 is used as a secondary control as it does not inhibit MTD. Compound 3 is the original compound, 3-deazaneplanocin A. Therefore, we have further 3 compounds (1, 2 and 4) that may be effective in vivo treatment of liver fibrosis aside from the originally described one.

Table 1










Compound No.	Structure	MF/MW
1		$C_{11}H_{13}N_5O_3$ /263.3
2		$C_{14}H_{18}ClN_5O_3$ /339.8
3		$C_{12}H_{15}ClN_4O_3$ /298.7
4		$C_{20}H_{28}N_4O_4$ /388.5
5		$C_{12}H_{14}FN_4O_3$ /316.1

Table 1 (cont'd)

6		$C_{12}H_{14}Cl_2N_4O_3$ /333.2
7		$C_{12}H_{15}N_5O_3$ /277.3
8		$C_{10}H_{11}ClN_4O_3$ /270.7
9		$C_8H_{12}N_4O_5$ /244.2


References

1. Yavrom S, Chen L, Xiong S, Wang J, Rippe RA, Tsukamoto H. Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF- κ B binding to DNA in hepatic stellate cells. *J Biol Chem*. 2005 Dec 9;280(49):40650-9.
2. Klein ME, Liou DT, Ma L, Impey S, Mandel G, Goodman RH. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. *Nat Neurosci*. 2007 Dec;10(12):1513-4.
3. Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. *Nucleic Acids Res*. 2003 May 1;31(9):2305-12.
4. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, Farnham PJ. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. *Genes Dev*. 2004 Jul 1;18(13):1592-605.
5. Schotta G, Lachner M, Peters A, H., and Jenuwein T. (2004) Novartis Found. Symp. 259, 22–47, 163–169.
6. Houghlum K, Lee KS, Chojkier M. Proliferation of hepatic stellate cells is inhibited by phosphorylation of CREB on serine 133. *J Clin Invest*. 1997 Mar 15;99(6):1322-8.
7. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. *Cell Death Differ*. 2007 Feb;14(2):275-85.
8. O'Neill LP, Turner BM. Immunoprecipitation of native chromatin: NChIP. *Methods*. 2003 Sep;31(1):76-82.
9. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. *Gastroenterology*. 2001 Sep;121(3):685-98.
10. Oakley F, Mann J, Nailard S, Smart DE, Mungalsingh N, Constandinou C, Ali S, Wilson SJ, Millward-Sadler H, Iredale JP, Mann DA. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. *Am J Pathol*. 2005 Mar;166(3):695-708.
11. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF. Gene expression profiles during hepatic stellate cell activation in culture and *in vivo*. *Gastroenterology*. 2007 May;132(5):1937-46.


12. Hui AY, Friedman SL. Molecular basis of hepatic fibrosis. *Expert Rev Mol Med*. 2003 Feb 14;5(5):1-23. Review.
13. Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. *J Gastroenterol Hepatol*. 2006 Oct;21 Suppl 3:S102-5. Review.
14. She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. *J Biol Chem*. 2005 Feb 11;280(6):4959-67.
15. Friedman SL. Mechanisms of hepatic fibrogenesis. *Gastroenterology*. 2008 May;134(6):1655-69. Review.
16. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, Clark N, Murphy G. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. *Hepatology*. 1996 Jul;24(1):176-84.
17. Klemm DJ, Leitner JW, Watson P, Nesterova A, Reusch JE, Goalstone ML, Draznin B. *J Biol Chem*. 2001 Jul 27;276(30):28430-5.
18. Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. *J Biol Chem*. 2004 Mar 19;279(12):11392-401.
19. Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. *Nucleic Acids Res*. 2003 May 1;31(9):2305-12.
20. Cheutin T, McNairn AJ, Jenuwein T, Gilbert DM, Singh PB, Misteli T. Maintenance of stable heterochromatin domains by dynamic HP1 binding. *Science*. 2003 Jan 31;299(5607):721-5.
21. Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. *Science*. 2004 Nov 26;306(5701):1574-7.
22. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science*. 2008 May 30;320(5880):1224-9.
23. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. *Physiol Rev*. 2008 Jan;88(1):125-72. Review.

Claims:

1. A method of inhibiting fibrogenesis, or treating a fibrotic disease or a secondary disease state or condition thereof comprising administering to a patient in need thereof a compound according to the chemical structure **Ia**:



Where B is



W is C-H, O or S such that the bond between W and the adjacent carbon atom is a double bond when W is C-H and a single bond when W is O or S;

V is C-A'', O or S;

A is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A' is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A'' is H or OR¹,

with the proviso that when A' is OR², A is H; and when A is OR², A' is H;

W is C-H, O or S such that the bond between W and the adjacent carbon atom is a double bond when W is C-H and a single bond when W is O or S;

X is C-R³ or N;

Y is C-R³ or N; preferably X or Y is N and X and Y are not both simultaneously N;

Rz is H or a C₁-C₃ alkyl group, optionally substituted with OH;

R^3 is H or C_1 - C_3 alkyl;

D is H or $NR^{1a}R^2$;

E is absent (when G is NHR^2) or H (when G is O);

G is O or $NR^{1a}R^2$;

J is N or $C-R^4$;

K is N or $C-H$;


R^4 is H, halogen (F, Cl, Br, I), CN, $-C(=O)NH_2$, NH_2 , NO_2 , $-C=C-H$ (cis or trans) or $-C\equiv C-H$;

R_a is H or CH_3 ;

Each R^1 is independently H, an acyl group, a C_1 — C_{20} alkyl or ether group, an amino acid (D or L), a phosphate, diphosphate, triphosphate, phosphodiester group;

Each R^{1a} and R^2 is independently H, an acyl group, a C_1 — C_{20} alkyl or ether group, an amino acid (D or L) or together R^{1a} and R^2 form a C_3 - C_7 cycloalkyl group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.


2. The method according to claim 1 wherein said compound has a chemical structure according to formula **Ib**:



Ib


Wherein B, A, A', A'' and R^1 are the same as described for formula **Ia** of claim 1.

3. The method according to claim 1 wherein W and V are both O.
4. The method according to claim 1 or 2 wherein A is OH, A' is H and A'' is OH, J is N or CR^4 , K is N or CH, X is N, Y is CR^3 , E is absent and G is NHR^2 .
5. The method according to claim 1 or 2 wherein A is OH, A' is H and A'' is OH, J is N or CR^4 , K is N or CH, X is N, Y is CR^3 , E is absent and G is NHR^2 .
6. The method according to any of claims 1-3 wherein J is N, K is CH and G is O or NHR^2 .
7. The method according to any of claims 1-2 and 4-6 wherein R^1 and R^2 are both H.
8. The method according to any of claims 1-7 wherein R^4 is an acetylenic group.
9. The method according to claim 1 wherein said compound is




Where R^1 , R^2 , R^4 , X and Y are the same as described above.

10. The method according to claim 1 wherein said compound is according to chemical structure **Ic**:




Where B' is



Or pharmaceutically acceptable salts, solvates or polymorphs thereof.


11. The method according to claim 1 wherein said compound is



Where D is H, F, Cl or Br, preferably F or Cl, more preferably Cl,
Or pharmaceutically acceptable salts, solvates or polymorphs thereof.


12. The method according to any of claims 1-11 wherein said compound is conjugated to an antibody which binds to MeCP₂ or EZH₂ (anti-MECP₂ or anti-EZH₂).
13. The method according to claim 12 wherein said antibody is a monoclonal antibody which binds to MeCP₂.
14. The method according to claim 12 wherein said antibody is a polyclonal antibody which binds to MeCP₂.
15. The method according to claim 12 wherein said antibody is a monoclonal antibody which binds to EXH₂.
16. The method according to claim 12 wherein said antibody is a polyclonal antibody which binds to EXH₂.
17. The method according to any of claims 1-16 wherein said fibrogenesis or said fibrotic disease is liver fibrosis, renal fibrosis, lung fibrosis, hypersensitivity pneumonitis, interstitial fibrosis, systemic scleroderma, macular degeneration, pancreatic fibrosis, fibrosis of the spleen, cardiac fibrosis, mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, fibrotic complications of surgery or injection fibrosis.
18. The method according to any of claims 1-16 wherein said secondary disease state or condition is cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome or rheumatoid arthritis.
19. The method according to any of claims 1-16 wherein said fibrogenesis is liver fibrogenesis.

20. The method according to any of claims 1-16 wherein said secondary disease state or condition is cirrhosis.
21. A method of inhibiting fibrogenesis or treating a fibrotic disease or a secondary disease state or condition thereof comprising administering to a patient in need thereof an antibody which binds to MeCP₂ or EZH₂.
22. The method according to claim 21 wherein said antibody is a monoclonal antibody which binds to MeCP₂.
23. The method according to claim 21 wherein said antibody is a polyclonal antibody which binds to MeCP₂.
24. The method according to claim 21 wherein said antibody is a monoclonal antibody which binds to EXH₂.
25. The method according to claim 21 wherein said antibody is a polyclonal antibody which binds to EXH₂.
26. The method according to any of claims 1-16 or 21-25 wherein said fibrogenesis or said fibrotic disease is liver fibrosis, renal fibrosis, lung fibrosis, hypersensitivity pneumonitis, interstitial fibrosis, systemic scleroderma, macular degeneration, pancreatic fibrosis, fibrosis of the spleen, cardiac fibrosis, mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, fibrotic complications of surgery or injection fibrosis.
27. The method according to any of claims 1-16 or 21-25 wherein said secondary disease state or condition is cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome or rheumatoid arthritis.
28. The method according to any of claims 21-25 wherein said fibrogenesis is liver fibrogenesis.
29. The method according to any of claims 21-25 wherein said secondary disease state or condition is cirrhosis.
30. A method of inhibiting methylation of polynucleotides in a cell comprising exposing a cell to an effective amount of a compound set forth in any of claims 1-16.
31. The method according to claim 30 wherein said polynucleotide is DNA.
32. The method according to claim 30 wherein said polynucleotide is RNA.
33. A pharmaceutical composition comprising an effective amount of a compound according to the chemical structure **Ia**:



Ia

Where B is



W is C-H, O or S (preferably C-H or O, more preferably C-H) such that the bond between W and the adjacent carbon atom is a double bond when W is C-H and a single bond when W is O or S;

V is C-A'', O or S;

A is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A' is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A'' is H or OR¹,

with the proviso that when A' is OR², A is H; and when A is OR², A' is H;

W is C-H, O or S such that the bond between W and the adjacent carbon atom is a double bond when W is C-H and a single bond when W is O or S;

X is C-R³ or N;

Y is C-R³ or N; preferably X or Y is N and X and Y are not both simultaneously N;

Rz is H or a C₁-C₃ alkyl group, optionally substituted with OH;

R³ is H or C₁-C₃ alkyl;

D is H or NR^{1a}R²;

E is absent (when G is NHR²) or H (when G is O);

G is O or NR^{1a}R²;

J is N or C-R⁴;


K is N or C-H;

R^4 is H, halogen (F, Cl, Br, I), CN, $-C(=O)NH_2$, NH_2 , NO_2 , $-C=C-H$ (cis or trans) or $-C\equiv C-H$;
 R_a is H or CH_3 ;

Each R^1 is independently H, an acyl group, a C_1-C_{20} alkyl or ether group, an amino acid (D or L), a phosphate, diphosphate, triphosphate, phosphodiester group;

Each R^{1a} and R^2 is independently H, an acyl group, a C_1-C_{20} alkyl or ether group, an amino acid (D or L) or together R^{1a} and R^2 form a C_3-C_7 cycloalkyl group; or a pharmaceutically acceptable salt, solvate or polymorph thereof, in combination with an antibody which binds to $MeCP_2$ or EZH_2 (anti- $MeCP_2$ or anti- EXH_2).


34. The composition according to claim 32 wherein said compound has a chemical structure according to formula **Ib**:



Ib


Wherein B, A, A', A'' and R^1 are the same as described for formula **Ia** of claim 32.

35. The composition according to claim 33 wherein W and V are both O.
36. The composition according to claim 33 or 34 wherein A is OH, A' is H and A'' is OH, J is N or CR^4 , K is N or CH, X is N, Y is CR^3 , E is absent and G is NHR^2 .
37. The composition according to claim 33 or 34 wherein A is OH, A' is H and A'' is OH, J is N or CR^4 , K is N or CH, X is N, Y is CR^3 , E is absent and G is NHR^2 .
38. The composition according to claim 33-35 wherein J is N, K is CH and G is O or NHR^2 .
39. The composition according to claim 33-39 wherein R^1 and R^2 are both H.
40. The composition according to any of claims 33-39 wherein R^4 is an acetylenic group.
41. The composition according to claim 33 or 34 wherein said compound is




Where R^1 , R^2 , R^4 , X and Y are the same as described for compound Ia in claim 32.

42. The composition according to claim 33 wherein said compound is according to chemical structure **Ic**:




Where B' is



Or pharmaceutically acceptable salts, solvates or polymorphs thereof.


43. The composition according to claim 33 wherein said compound is




Where D is H, F, Cl or Br, preferably F or Cl, more preferably Cl,
Or pharmaceutically acceptable salts, solvates or polymorphs thereof.

44. The composition according to any of claims 33-43 wherein said antibody is a monoclonal antibody which binds to MeCP₂.
45. The composition according to any of claims 33-43 wherein said antibody is a polyclonal antibody which binds to MeCP₂.
46. The composition according to any of claims 33-43 wherein said antibody is a monoclonal antibody which binds to EXH₂.
47. The composition according to any of claims 33-43 wherein said antibody is a polyclonal antibody which binds to EXH₂.
48. A pharmaceutical composition comprising an effective amount of an antibody which binds to MeCP₂ or EZH₂ (anti-MECP₂ or anti-EXH₂) in combination with a pharmaceutically acceptable carrier, additive or excipient.
49. The composition according to claim 48 wherein said antibody is a monoclonal antibody which binds to MeCP₂.
50. The composition according to claim 48 wherein said antibody is a polyclonal antibody which binds to MeCP₂.
51. The composition according to claim 48 wherein said antibody is a monoclonal antibody which binds to EXH₂.
52. The composition according to claim 48 wherein said antibody is a polyclonal antibody which binds to EXH₂.

53. Use of a compound in the manufacture of a medicament for inhibiting fibrogenesis, or treating a fibrotic disease or a secondary disease state or condition thereof wherein said compound is according to the chemical structure **Ia**:



Where B is



W is C-H, O or S such that the bond between W and the adjacent carbon atom is a double bond when W is C-H and a single bond when W is O or S;

V is C-A'', O or S;

A is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A' is H, OR² or halogen (F, Cl, Br, I, preferably F or Br, more preferably F);

A'' is H or OR¹,

with the proviso that when A' is OR², A is H; and when A is OR², A' is H;

W is C-H, O or S such that the bond between W and the adjacent carbon atom is a double bond when W is C-H and a single bond when W is O or S;

X is C-R³ or N;

Y is C-R³ or N; preferably X or Y is N and X and Y are not both simultaneously N;

Rz is H or a C₁-C₃ alkyl group, optionally substituted with OH;

R³ is H or C₁-C₃ alkyl;

D is H or NR^{1a}R²;

E is absent (when G is NHR²) or H (when G is O);

G is O or NR^{1a}R^2 ;

J is N or C-R^4 ;

K is N or C-H;


R^4 is H, halogen (F, Cl, Br, I), CN, $-\text{C}(=\text{O})\text{NH}_2$, NH_2 , NO_2 , $-\text{C}=\text{C}-\text{H}$ (cis or trans) or $-\text{C}\equiv\text{C}-\text{H}$;

R_a is H or CH_3 ;

Each R^1 is independently H, an acyl group, a $\text{C}_1\text{—C}_{20}$ alkyl or ether group, an amino acid (D or L), a phosphate, diphosphate, triphosphate, phosphodiester group;

Each R^{1a} and R^2 is independently H, an acyl group, a $\text{C}_1\text{—C}_{20}$ alkyl or ether group, an amino acid (D or L) or together R^{1a} and R^2 form a $\text{C}_3\text{—C}_7$ cycloalkyl group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.

54. The use according to claim 53 wherein said compound has a chemical structure according to formula **Ib**:



Ib

Wherein B, A, A', A'' and R^1 are the same as described for formula **Ia** of claim 1.

55. The use according to claim 53 wherein W and V are both O.

56. The use according to claim 53 or 54 wherein A is OH, A' is H and A'' is OH, J is N or CR^4 , K is N or CH, X is N, Y is CR^3 , E is absent and G is NHR^2 .


57. The use according to claim 53 or 54 wherein A is OH, A' is H and A'' is OH, J is N or CR^4 , K is N or CH, X is N, Y is CR^3 , E is absent and G is NHR^2 .

58. The use according to any of claims 53-55 wherein J is N, K is CH and G is O or NHR^2 .

59. The use according to any of claims 53-54 and 56-58 wherein R^1 and R^2 are both H.


60. The use according to any of claims 53-59 wherein R^4 is an acetylenic group.

61. The use according to claim 53 wherein said compound is




Where R^1 , R^2 , R^4 , X and Y are the same as described above.

62. The use according to claim 53 wherein said compound is according to chemical structure **Ic**:




Where B' is



Or pharmaceutically acceptable salts, solvates or polymorphs thereof.

63. The use according to claim 53 wherein said compound is



Where D is H, F, Cl or Br, preferably F or Cl, more preferably Cl,

Or pharmaceutically acceptable salts, solvates or polymorphs thereof.

64. The use according to any of claims 53-63 wherein said compound is conjugated to an antibody which binds to MeCP₂ or EZH₂ (anti-MECP₂ or anti-EZH₂).
65. The use according to claim 64 wherein said antibody is a monoclonal antibody which binds to MeCP₂.
66. The use according to claim 64 wherein said antibody is a polyclonal antibody which binds to MeCP₂.
67. The use according to claim 64 wherein said antibody is a monoclonal antibody which binds to EXH₂.
68. The use according to claim 64 wherein said antibody is a polyclonal antibody which binds to EXH₂.
69. The use according to any of claims 53-68 wherein said fibrogenesis or said fibrotic disease is liver fibrosis, renal fibrosis, lung fibrosis, hypersensitivity pneumonitis, interstitial fibrosis, systemic scleroderma, macular degeneration, pancreatic fibrosis, fibrosis of the spleen, cardiac fibrosis, mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, fibrotic complications of surgery or injection fibrosis.
70. The use according to any of claims 53-68 wherein said secondary disease state or condition is cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome or rheumatoid arthritis.
71. The use according to any of claims 53-68 wherein said fibrogenesis is liver fibrogenesis.

72. The use according to any of claims 53-68 wherein said secondary disease state or condition is cirrhosis.
73. Use of an antibody which binds to MeCP₂ or EZH₂ for inhibiting fibrogenesis or treating a fibrotic disease or a secondary disease state or condition thereof.
74. The use according to claim 73 wherein said antibody is a monoclonal antibody which binds to MeCP₂.
75. The use according to claim 73 wherein said antibody is a polyclonal antibody which binds to MeCP₂.
76. The use according to claim 73 wherein said antibody is a monoclonal antibody which binds to EXH₂.
77. The use according to claim 73 wherein said antibody is a polyclonal antibody which binds to EXH₂.
78. The use according to any of claims 53-68 or 73-77 wherein said fibrogenesis or said fibrotic disease is liver fibrosis, renal fibrosis, lung fibrosis, hypersensitivity pneumonitis, interstitial fibrosis, systemic scleroderma, macular degeneration, pancreatic fibrosis, fibrosis of the spleen, cardiac fibrosis, mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, fibrotic complications of surgery or injection fibrosis.
79. The use according to any of claims 53-68 or 73-77 wherein said secondary disease state or condition is cirrhosis, diffuse parenchymal lung disease, post-vasectomy pain syndrome or rheumatoid arthritis.
80. The use according to any of claims 73-77 wherein said fibrogenesis is liver fibrogenesis.
81. The use according to any of claims 73-77 wherein said secondary disease state or condition is cirrhosis.
82. Use of a compound according to any of claims 1-16 in the manufacture of a medicament for inhibiting methylation of polynucleotides in a cell.
83. Use according to claim 82 wherein said polynucleotide is DNA.
84. Use according to claim 82 wherein said polynucleotide is RNA.

FIGURE 1




FIGURE 2





Figure 3






Figure 4





FIGURE 5







FIGURE 6

CpG island starts at -372, encompasses exon A1 and 626bp of intron 1.

FIGURE 7

**CpG island**

Start at -372 from the start of A1 exon, extends over the A1 exon and 626bp into intron 1.

%CG=59.8, length of the island is 1412bp.

FIGURE 8




FIGURE 9




FIGURE 10A






FIGURE 10B


Morphology at day 7





Control




Compound 1



Compound 2

Compound 3
DZNep

Compound 4



Compound 9

FIGURE 11

